Abstract 402P
Background
Cancer survivors have been reported to face challenges as they return to work after completing antineoplastic treatment. In order to understand the burden of return-to-work challenges among cancer survivors in Singapore, we aim to describe the work-related outcomes, including employment rates, absenteeism and presenteeism, among local cancer survivors.
Methods
This was a cross-sectional study conducted at the National Cancer Centre Singapore in 2018. Breast cancer, colorectal cancer and lymphoma survivors who were in disease remission and have completed treatment for at least 6 months were recruited. Employment history and absenteeism data in the past 6 months were collected using self-administered questionnaires. Presenteeism was self-reported using the Work Limitations Questionnaire.
Results
A total of 501 patients were recruited. Most participants were Chinese (79.6%), followed by Malay (11.8%), Indian (4.6%) and other ethnicities (4.0%). Over half were breast cancer survivors (69.5%), followed by colorectal cancer (15.5%) and lymphoma (15.0%) survivors. The median age of the participants was 55.7 years (IQR: 50.1 to 60.5 years) while the median time after primary treatment completion was 3.7 years (IQR: 1.9 to 6.1 years). The majority of cancer survivors were employed with most participants reporting working full-time (47.5%), followed by part-time workers (10.2%) and self-employed individuals (5.8%). Out of the survivors who did not have paid employment, a substantial proportion (24.3%) were unemployed due to health-related reasons. Among employed participants, 56.9% reported taking time off work due to ill health or to see a physician in the past 6 months. The median absenteeism rate reported among working survivors was 0.8% of working time (range: 0 to 73.1%) while the median presenteeism or productivity loss at work due to health-related problems was reported to be 1.2% (range: 0 to 20.3%).
Conclusions
A significant proportion of cancer survivors in Singapore require time off from work or leave employment due to health-related issues. Further studies should be conducted to identify survivors who are at high risk for return-to-work challenges and should be offered occupational rehabilitation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Singapore Cancer Society.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
51P - Enhancing the anti-breast tumour activity of STING through a novel sting transcriptional regulator
Presenter: Hanchu Xiong
Session: Poster display session
Resources:
Abstract
52P - Reverse Warburg effect-related mitochondrial activity and 18F-FDG uptake in invasive ductal carcinoma
Presenter: Byung Wook Choi
Session: Poster display session
Resources:
Abstract
53P - Phase II study of atorvastatin in combination with radiotherapy and temozolomide in patients with glioblastoma (ART): Final analysis report
Presenter: Abdullah Altwairgi
Session: Poster display session
Resources:
Abstract
54P - Association between Parkinson’s disease and brain tumours: A nationwide population-based cohort study
Presenter: Joo-hyun Park
Session: Poster display session
Resources:
Abstract
55P - Toxicity profiles of treatment with modern fractionated radiotherapy, contemporary stereotactic radiosurgery, or transsphenoidal surgery in non-functioning pituitary macroadenoma
Presenter: Kevin Sheng-Po Yuan
Session: Poster display session
Resources:
Abstract
56P - Hippocampal avoidance in WBRT for metastases: Comparative neurocognitive and dosimetric assessment
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
57P - Multidisciplinary brain metastasis clinic: Is it effective and worthwhile?
Presenter: Annu Rajpurohit
Session: Poster display session
Resources:
Abstract
58P - Functional status as a determinant prognostic factor for overall survival in adult patients with medulloblastoma treated with chemotherapy and radiotherapy
Presenter: Juan Ayala Alvarez
Session: Poster display session
Resources:
Abstract
59P - Pattern of care in high-grade gliomas after recurrence
Presenter: Nandini Menon
Session: Poster display session
Resources:
Abstract
60P - Five fractions plus “SRS” boost combined with temozolamide for newly diagnosed and recurrent glioblastoma multiforme (GBM)
Presenter: Azhar Rashid
Session: Poster display session
Resources:
Abstract